| 摘要(英) |
Liver X receptors are nuclear hormone receptors that have been shown to play a major role in atherosclerosis by modulating cholesterol and triglyceride metabolism. Using human U937 monocyte and macrophage, we studied whether the three LXR agonists, such as T0901317, GW3965 and ATI-111, differentially affected mRNA expression of LXRα, LXRβ, and their downstream genes. Generally, these three LXR agonists dose- and time-dependently stimulated LXRα and SREBP-1c mRNA expression and decreased levels of MCP-1 and CCL5 mRNAs, but unaltered levels of LXRβ, RXRα, resistin and CD11c mRNAs. In U937 monocyte, the effective concentrations of T0901317, GW3965 and ATI-111 to increase 50% expression (EC50) were 9, 15 and 31 nM on LXRα gene and 3, 14 and 7 nM on SREBP-1c gene, respectively. The half maximal inhibitory concentrations of T0901317, GW3965 and ATI-111 were 265, 460 and 149 nM on MCP-1 gene and 1037, 472 and 334 nM on CCL-5 gene, respectively. In U937 macrophage, the EC50s of T0901317, GW3965 and ATI-111 to increase expression were 6, 12 and 0.4 nM on LXRα and 0.9, 9 and 5 nM on SREBP-1c gene, respectively. The half maximal inhibitory concentrations of T0901317, GW3965 and ATI-111 were 34, 80 and 253 nM on MCP-1 gene and 69, 34 and 23 nM on CCL-5 gene, respectively. These data suggest that the biological potencies of these three LXR agonists vary with the development status, the dose of treatment, and target genes. Further study showed that glucose alone increased levels of RXRα, SREBP-1c, MCP-1, CCL5 and resistin mRNAs and decreased levels of LXRα and LXRβ mRNAs. Increases in the level of LXRα mRNA expressioin stimulated by LXR agonist would be enhanced in monocyte and decreased in macrophage by glucose pretreatment. However, glucose reduced the LXR agonist-induced increases in levels of LXRβ, RXRα, SREBP-1c, MCP-1 and CCL5 mRNAs. These data indicate the nutritional status-dependent effect of these three LXR agonists. As LXRα, SREBP-1c, MCP-1 and CCL-5 have been respectively reported to regulate lipid metabolism and inflammation, results of the study may help explain the effect of these three LXR agonists on inflammation-related disease. |
| 參考文獻 |
1. Apfel R, et al. 1994. A Novel Orphan Receptor Specific for a Subset of Thyroid Hormone-Responsive Elements and Its Interaction with the Retinoid/Thyroid Hormone Receptor Subfamily. American Society for Microbiology 14:7025-7035.
2. Song C, et al. 1994. Ubiquitous receptor: A receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proceedings of the National Academy of Sciences 91:10809-10813.
3. Repa JJ, Mangelsdorf DJ. 2000. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. annual reviews 16:459-481.
4. Pascual-García M, et al. 2012. Biological roles of liver X receptors in immune cells.
Archivum immunologiae et therapiae experimentalis 60:235-249.
5. Schroepfer GJ Jr. 200. Oxysterols: Modulators of Cholesterol Metabolism and Other Processes. Physiological review 80:361-466.
6. Janowski BA, et al. 1996. An oxysterol signaling pathway mediated by the nuclear receptor LXRα. Nature 383:728-731.
7. Lehmann JM, et al. 1997. Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway. The journal of biological chemistry 272:3137-3140.
8. Ruan B, et al. 1998. an alternative synthesis of 4,4-dimethyl-5α-cholesta-8,14,24-
trien-3β-ol, an intermediate in sterol biosynthesis and a reported activator of meiosis and of nuclear orphan receptor LXRα. Bioorganic & medicinal chemistry letters 8:233-236.
9. Yang C, et al. 2006. Sterol Intermediates from Cholesterol Biosynthetic Pathway as Liver X Receptor Ligands. The journal of biological chemistry 281:27816-27826.
10. Song C, Liao S. 2000. Cholestenoic Acid Is a Naturally Occurring Ligand for Liver X Receptor α. Endocrinology 141:4180-4184.
11. Plat J, et al. 2005. Plant sterols and stanols: effects on mixed micellar composition and LXR (target gene) activation. Journal of Lipid Research 46:2468-2476.
12. Huang TH, et al. 2005. A novel LXRα activator identified from the natural product Gynostemma pentaphyllum. Biochemical Pharmacology 70:1298-1308.
13. Jayasuriya H, et al. 2005. Diterpenoid, Steroid, and Triterpenoid Agonists of Liver X Receptors from diversified Terrestrial Plants and Marine Sources. Journal of natural products 68:1247-1252.
14. Singh SB, et al. 2005. Discovery and development of dimeric podocarpic acid leads as potent agonists of liver X receptor with HDL cholesterol raising activity in mice and hamsters. Bioorganic & Medicinal Chemistry Letters 15:2824-2828.
15. Kotani H, et al. 2010. Identification of a Naturally Occurring Rexinoid, Honokiol, That Activates the Retinoid X Receptor. Journal of natural products 73:1332-1336.
16. Peet DJ, et al. 1998. The LXRs: a new class of oxysterol receptors. Current opinion in genetics & development 8:571-575.
17. Li X, et al. 2010. Liver X receptor modulators: a review of recently patented compounds (2007 – 2009). Expert opinion on therapeutic patents 20:535-562.
18. Houck KA, et al. 2004. T0901317 is a dual LXR/FXR agonist. Molecular genetics and metabolism 83:184-187.
19. Mitro N, et al. 2007. T0901317 is a potent PXR ligand: Implications for the biology ascribed to LXR. FEBS Letters 581:1721-1726.
20. Shenoy SD, et al. 2004. Cyp3a induction by liver x receptor ligands in primary cultured rat and mouse hepatocytes is mediated by the pregnane x receptor. The american society for pharmacology and experimental therapeutics. 32:66-71.
21. Joseph SB, et al. 2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proceedings of the National Academy of Sciences 99:7604-7609.
22. Yasuda T, et al. 2010. Tissue-Specific Liver X Receptor Activation Promotes Macrophage Reverse Cholesterol Transport In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology 30:781-786.
23. Kaneko E, et al. 2003. Induction of Intestinal ATP-binding Cassette Transporters by a Phytosterol-derived Liver X Receptor Agonist. The journal of biological chemistry 278:36091-36098.
24. Quinet EM, et al. 2004. Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor. Journal of lipid research 45:1929-1942.
25. DiBlasio-Smith EA, et al. 2008. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. Journal of translational medicine. 6:1-15.
26. Katz A, et al. 2009. Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR-623, a Novel Liver X Receptor Agonist, in Healthy Participants. The Journal of clinical pharmacology 49:643-649.
27. Hu B, et al. 2010. Identification of Phenylsulfone-Substituted Quinoxaline (WYE-672) as a Tissue Selective Liver X-receptor(LXR) Agonist. Journal of medicinal chemistry 53:3296-3304.
28. Peng D, et al. 2011. A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR–/– mice. British journal of pharmacology 162:1792-1804.
29. Aravindhan K, et al. 2006. Assessing the effects of LXR agonists on cellular cholesterol handling: a stable isotope tracer study. Journal of Lipid Research 47:1250-1260.
30. Venkateswaran A, et al. 2000. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα. Proceedings of the National Academy of Sciences 97:12097-12102.
31. Baldán A, et al. 2009. The ABCs of sterol transport. Journal of Lipid Research S80-S85.
32. Yu L, et al. 2003. Stimulation of Cholesterol Excretion by the Liver X Receptor Agonist Requires ATP-binding Cassette Transporters G5 and G8. The journal of biological chemistry 278:15565-15570.
33. Cao G, et al. 2002. Antidiabetic Action of a Liver X Receptor Agonist Mediated By Inhibition of Hepatic Gluconeogenesis. The journal of biological chemistry 278:1131-1136.
34. Laffitte BA, et al. 2003. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proceedings of the National Academy of Sciences 100:5419-5424.
35. Lee JH, et al. 2009. Differential SUMOylation of LXRα and LXRβ Mediates Transrepression of STAT1 Inflammatory Signaling in IFN-γ-Stimulated Brain Astrocytes. Molecular Cell 35:806-817.
36. Crisafulli C, et al. 2010. Effects of Liver x receptor agonist treatment on signal transduction pathways in acute lung inflammation. Respiratory research 11:1-15.
37. Park MC, et al. 2010. Liver X receptor agonist prevents the evolution of collagen-induced arthritis in mice. Rheumatology 49:882-890.
38. Fukuchi J, et al. 2004. Androgenic Suppression of ATP-binding Cassette Transporter A1 Expression in LNCaP Human Prostate Cancer Cells. Cancer research 64:7682-7685.
39. Pommier AJ, et al. 2010. Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene 29:2712-2723.
40. Viennois E, et al. 2012. LXRα Regulates the Androgen Response in Prostate Epithelium. Endocrinology 153: 3211–3223.
41. Uno S,et al. 2009. Suppression of beta-catenin signaling by liver X receptor ligands. Biochemical pharmacology 77:186-195.
42. Koldamova RP, et al. 2005. The Liver X Receptor Ligand T0901317 Decreases Amyloid Production in Vitro and in a Mouse Model of Alzheimer’s Disease. The journal of biological chemistry 280:4079-4088.
43. Fitz NF, et al. 2010. Liver X Receptor Agonist Treatment Ameliorates Amyloid Pathology and Memory Deficits Caused by High-Fat Diet in APP23 Mice. The Journal of neuroscience 30:6862-6872.
44. Peng D, et al. 2011. A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR–/– mice. British journal of pharmacology 162:1792-1804.
45. Pehkonen P, et al. 2012. Genome-wide landscape of liver X receptor chromatin binding and gene regulation in human macrophages. BMC Genomics 13:1-20.
46. Yokoyama C, et al. 1993. SREBP-1,basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoproteinreceptor gene. Cell 75:187-197.
47. Carr MW, et al. 1994. Monocyte chemoattractant rotein acts as T-lymphocyte chemoattractant. Proceedings of the National Academy of Sciences 91:3652-3656.
48. Craig MJ, et al. 2006. CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer metastasis reviews 25:611-619.
49. Xia M, et al. 2009. Recent developments in CCR2 antagonists. Expert opinion on therapeutic patents 19:295-303.
50. Donlon TA, et al. 1990. Localization of a human T-cell-specific gene, RANTES (D17S136E), to chromosome 17q11.2-q12. Genomics 6:548-553.
51. Cocchi F, et al. 1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270:1811-1815.
52. Steppan CM, et al. 2001. The hormone resistin links obesity to diabetes.Nature 409:307-312.
53. Silswal N, et al. 2005. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochemical and biophysical research communications 334:1092-1101.
54. Stewart M, et al. 1995. Leukocyte integrins. Current opinion in cell biology 7:690-696.
55. Chen J, et al. 2012. Liver X receptor activation attenuates plaque formation and improves vasomotor function of the aortic artery in atherosclerotic ApoE−/− mice. Inflammation Research 61:1299-1307.
56. Mitro N, et al. 2007. The nuclear receptor LXR is a glucose sensor. Nature 445:219-223.
57. Seo JB, et al. 2003. Functional Characterization of the Human Resistin Promoter with Adipocyte Determination- and Differentiation-Dependent Factor 1/Sterol Regulatory Element Binding Protein 1c and CCAAT Enhancer Binding Protein-α. Molecular Endocrinology 17:1522-1533.
58. Gao M, et al. 2013. Concurrent Activation of Liver X Receptor and Peroxisome Proliferator-Activated Receptor Alpha Exacerbates Hepatic Steatosis in High Fat Diet-Induced Obese Mice. PLOS ONE 8:1-11.
59. Laffitte BA, et al. 2001. Autoregulation of the human liver X receptor alpha promoter. Molecular and cellular biology 21:7558-7568.
60. Ueda A, et al. 1994. NF-kappaB and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. The Journal of immunology 153:2052-2063.
61. Canavan M, et al. 2013. Activation of liver X receptor suppresses the production of the IL-12 family of cytokines by blocking nuclear translocation of NF-κBp50. Innate Immunity. 1-13.
62. Whitney KD, et al. 2001. Liver X Receptor (LXR) Regulation of the LXRα Gene in Human Macrophages. The journal of biological chemistry 276:43509-43515.
63. Oberg F, et al. 1993. Functional Antagonism between Vitamin D3 and Retinoic Acid in the Regulation of CD14, and CD23 Expression during Monocytic Differentiation of U-937 Cells. The journal of immunology 150:3487-3495.
64. Delvecchio CJ, et al. 2008. Protein kinase C a modulates liver X receptor a transactivation. Journal of Endocrinology 197:121-130.
65. Liu W, et al. 2013. Phospho-GSK-3 is involved in the high-glucose-mediated lipid deposition in renal tubular cells in diabetes. The International Journal of Biochemistry & Cell Biology 45:2066-2075.Crystal Rocher,Dinender K. Singla. 2013. SMAD-PI3K-Akt-mTOR Pathway Mediates BMP-7 Polarization of Monocytes into M2 Macrophages. PLOS one 8:1-9.
66. Behre G, et al. 2002. Ras Signaling Enhances the Activity of C/EBPα to Induce Granulocytic Differentiation by Phosphorylation of Serine 248. The journal of biological chemistry 277:26293-26299.
67. Liu D, et al. 2013. Effects of exposure to high glucose on primary cultured hippocampal neurons: involvement of intracellular ROS accumulation. Neurological sciences.
68. Alba G, et al. 2012. Transcription of Liver X Receptor Is Down-Regulated by 15-Deoxy-△12,14-Prostaglandin J(2) through Oxidative Stress in Human Neutrophils. PLOS one 7:1-13.
69. Delvecchio CJ, et al. 2008. Protein kinase C a modulates liver X receptor a transactivation. Journal of Endocrinology 197:121-130.
70. Louet JF, et al. 2010. The Coactivator SRC-1 Is an Essential Coordinator of Hepatic Glucose Production. Cell metabolism 12:606-618.
71. Helleboid-Chapman A, et al. 2006. Glucose regulates LXRα subcellular localization and function in rat pancreatic β-cells. Cell Research 16:661-670.
72. Ning RB, et al. 2013. RXR agonists inhibit high glucose-induced upregulation of inflammation by suppressing activation of the NADPH oxidase-nuclear factor-κB pathway in human endothelial cells. Genetics and Molecular Research 12:6692-6707.
73. Stan D, et al. 2011. High glucose induces enhanced expression of resistin in human U937 monocyte-like cell line by MAPK- and NF-kB-dependent mechanisms; the modulating effect of insulin. Cell Tissue Research 343:379-387.
74. Nohara A, et al. 2009. Retinoid X receptor heterodimer variants and cardiovascular risk factors. Journal of atherosclerosis and thrombosis 16:303-318.
75. Su H, et al. 2012. Glucose Enhances Leptin Signaling through Modulation of AMPK Activity. PLOS one 7:1-7.
76. Yap F, et al. 2011. Mechanism of AMPK Suppression of LXR-dependent Srebp-1c Transcription. International journal of biological sciences 7:645-650.
77. Zhang-Gandhi CX, et al. 2007. Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes. Journal of Neuroimmunology 183:50-59.
78. Génin P, et al. 2000. Regulation of RANTES chemokine gene expression requires cooperativity between NF-kappaB and IFN-regulatory factor transcription factors. The Journal of immunology 164:5352-5361.
79. Steppan CM, et al. 2001. The hormone resistin links obesity to diabetes. Nature 409:307-312.
80. Jakobsson T, et al. 2012. Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. Trends in Pharmacological Sciences 33:394-404. |
[Endnote RIS 格式]
[相關文章]
[文章引用]
[完整記錄]
[館藏目錄]
[檢視]
plurk
funp
live
udn
HD
myshare
netvibes
friend
youpush
delicious
baidu
Google bookmarks
del.icio.us
hemidemi
facebook
twitter
google
reddit